News

Fierce Biotech24m
GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...
Fierce Biotech58m
Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'
Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...